Wire · opportunities
Karmanos now offers FDA-approved Daraxonrasib (Rasonque) for metastatic pancreatic cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
The Barbara Ann Karmanos Cancer Institute now offers FDA-approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have failed prior systemic therapy or are ineligible for multiagent chemotherapy. The phase III RASolute 302 trial demonstrated daraxonrasib significantly improved median overall survival compared to standard chemotherapy.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now expand pancreatic cancer treatment options beyond chemotherapy using FDA-approved daraxonrasib, potentially improving patient outcomes. Oncologists and biotech founders should prioritise partnerships that integrate this targeted oral therapy into care pathways.
◆ Coverage
1 source · 1 Sep 2026
◆ Related on Wire
◆ Topics